Suchbegriffe: SECOND LINE THERAPY, . Treffer: 6
Müller, M; Posch, F; Kiem, D; Barth, D; Horvath, L; Stotz, M; Schaberl-Moser, R; Pichler, M; Greil, R; Jost, PJ; Seeber, A; Amann, A; Schlick, K; Gerger, A; Riedl, JM
Benefit of second-line therapy for advanced esophageal squamous cell carcinoma: a tri-center propensity score analysis.
Ther Adv Med Oncol. 2021; 13: 17588359211039930
Doi: 10.1177/17588359211039930
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Manninger, M; Ebner, J; Zweiker, D; Sieghartsleitner, R; Mastnak, B; Bisping, E; Lercher, P; Riedlbauer, R; Rotman, B; Brussee, H; Scherr, D
Is there a difference in rhythm outcome between patients undergoing first line versus second line paroxysmal atrial fibrillation ablation?
PLoS One. 2018; 13(12):e0208994-e0208994
Doi: 10.1371/journal.pone.0208994
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Brodmann, M; Gary, T; Pilger, E
Massive pulmonary embolism in spite of temporary vena caval filter.
VASA. 2010; 39(1): 111-114.
Doi: 10.1024/0301-1526/a000014
(- Case Report)
Web of Science
PubMed
FullText
FullText_MUG
Zuliani, G; Galvani, M; Leitersdorf, E; Volpato, S; Cavalieri, M; Fellin, R
The role of polyunsaturated fatty acids (PUFA) in the treatment of dyslipidemias.
Curr Pharm Des. 2009; 15(36):4087-4093
Doi: 10.2174/138161209789909773
Web of Science
PubMed
FullText
FullText_MUG
Hilbe, W; Aigner, K; Dittrich, C; Eckmayr, J; Fiegl, M; Flicker, M; Forstner, B; Greil, R; Jamnig, H; Krajnik, G; Lang, A; Mohn-Staudner, A; Schinko, H; Studnicka, M; Pirker, R; Ploner, F; Rothmund, J; Schiller, L; Zabernigg, A; Zöchbauer-Müller, S
Expert recommendations 2006 on the rationale for second-line therapy for non-small cell bronchial neoplasms
WIEN KLIN WOCHENSCHR. 2007; 119(7-8): 259-266.
Doi: 10.1007/s00508-007-0792-5
Web of Science
PubMed
FullText
FullText_MUG
Ploner, F
NSCLC: update on second line therapy following ASCO 2007
Wien Med Wochenschr. 2007; 157(21-22): 540-544.
Doi: 10.1007/s10354-007-0481-z
PubMed
FullText
FullText_MUG